Cargando…
Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
Since worsening renal function (WRF) and atrial fibrillation (AF) often coexist in preserved ejection fraction (HFpEF), we aimed to investigate the effect of WRF on the prognosis of HFpEF patients with and without AF. The study population of this study (n = 1763) was based on the subset of the Ameri...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526122/ https://www.ncbi.nlm.nih.gov/pubmed/37760925 http://dx.doi.org/10.3390/biomedicines11092484 |
_version_ | 1785110946910306304 |
---|---|
author | Guo, Linjuan Wu, Xiaojuan |
author_facet | Guo, Linjuan Wu, Xiaojuan |
author_sort | Guo, Linjuan |
collection | PubMed |
description | Since worsening renal function (WRF) and atrial fibrillation (AF) often coexist in preserved ejection fraction (HFpEF), we aimed to investigate the effect of WRF on the prognosis of HFpEF patients with and without AF. The study population of this study (n = 1763) was based on the subset of the Americas in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). We found that the cumulative probabilities of the primary composite outcome and cardiovascular death were significantly higher in AF patients post-WRF when compared to non-AF patients. In the time-dependent Cox proportional hazard model, WRF was significantly associated with higher risks of adverse outcomes (primary composite outcome: HR = 1.58 (95% CI, 1.19–2.11); all-cause death: HR = 1.50 (95% CI, 1.10–2.06); cardiovascular death: HR, 2.00 (95% CI, 1.34–3.00)) after adjustments for confounding factors at baseline in HFpEF patients with AF, whereas in HFpEF patients without AF, WRF was not significantly associated with any adverse outcome. p for interactions for the primary composite outcome, cardiovascular death, and AF were significant. In conclusion, these findings highlight that WRF was associated with a greater risk of the primary composite outcome, all-cause death, and cardiovascular death in HFpEF patients with AF. |
format | Online Article Text |
id | pubmed-10526122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105261222023-09-28 Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation Guo, Linjuan Wu, Xiaojuan Biomedicines Article Since worsening renal function (WRF) and atrial fibrillation (AF) often coexist in preserved ejection fraction (HFpEF), we aimed to investigate the effect of WRF on the prognosis of HFpEF patients with and without AF. The study population of this study (n = 1763) was based on the subset of the Americas in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). We found that the cumulative probabilities of the primary composite outcome and cardiovascular death were significantly higher in AF patients post-WRF when compared to non-AF patients. In the time-dependent Cox proportional hazard model, WRF was significantly associated with higher risks of adverse outcomes (primary composite outcome: HR = 1.58 (95% CI, 1.19–2.11); all-cause death: HR = 1.50 (95% CI, 1.10–2.06); cardiovascular death: HR, 2.00 (95% CI, 1.34–3.00)) after adjustments for confounding factors at baseline in HFpEF patients with AF, whereas in HFpEF patients without AF, WRF was not significantly associated with any adverse outcome. p for interactions for the primary composite outcome, cardiovascular death, and AF were significant. In conclusion, these findings highlight that WRF was associated with a greater risk of the primary composite outcome, all-cause death, and cardiovascular death in HFpEF patients with AF. MDPI 2023-09-07 /pmc/articles/PMC10526122/ /pubmed/37760925 http://dx.doi.org/10.3390/biomedicines11092484 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guo, Linjuan Wu, Xiaojuan Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title | Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title_full | Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title_fullStr | Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title_full_unstemmed | Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title_short | Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation |
title_sort | worsening renal function and adverse outcomes in patients with hfpef with or without atrial fibrillation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526122/ https://www.ncbi.nlm.nih.gov/pubmed/37760925 http://dx.doi.org/10.3390/biomedicines11092484 |
work_keys_str_mv | AT guolinjuan worseningrenalfunctionandadverseoutcomesinpatientswithhfpefwithorwithoutatrialfibrillation AT wuxiaojuan worseningrenalfunctionandadverseoutcomesinpatientswithhfpefwithorwithoutatrialfibrillation |